Legal Notice

 

The Pharmacy Show is sponsored by the pharmaceutical and med tech industries via Grants, Sponsorship, and Exhibition packages. Pharmaceutical companies have solely provided sponsorship through the purchase of exhibition space and/or sponsored speaker sessions with no further input into the arrangements or agenda of the meeting. Sessions delivered with input from our sponsors will always be marked on the programme. A full list of confirmed sponsors for PS24 is available here.

 

 

NEC BIRMINGHAM
12-13 OCTOBER 2025

24 Sep 2024

Acnecide+Purifide exhibiting at The Pharmacy Show 2024, The NEC Birmingham

Galderma Hall: 4 Stand: H67
Acnecide + Purifide
Acnecide+Purifide exhibiting at The Pharmacy Show 2024, The NEC Birmingham
Your Clearer Skin Routine with Acnecide + Purifide
Birmingham – Acnecide+Purifide will be exhibiting at The Pharmacy Show, The NEC Birmingham from 13th – 14th October 2024.

Acnecide+Purifide are the experts in clearer skin, using the latest dermatology science and expert approaches for acne treatments and dermacosmetic skincare for clear skin. Acnecide is the UK’s no.1 selling acne treatment brand and Purifide is a range of smart skincare for spot and blemish-prone skin.

 

Acnecide+Purifide will be exhibiting at stand H67, near Public Health and Wellbeing Theatre at The NEC Birmingham and showcasing its range of medicinal treatments and dermacosmetic skincare to all attendees. Head over to stand H67 from 9am to 6pm on Sunday 13th October, and 9am to 4:30pm on Monday 14th October to learn more about its range of Acnecide treatments as well as its latest product launch – the Purifide Power Patches.

 

Acnecide treatments, which use 5% Benzoyl Peroxide, effectively target the 3 main causes of acne: bacteria, clogged pores and excess oil. The latest Purifide product launch, Power Patches, are a 3-in-1 action designed to help visibly soothe and reduce spots as well as redness in just four hours.

 

The patches are placed directly on an emerging blemish to stop it in its tracks. Ultra-thin and invisible, they are packed with spot-busting ingredients such as Salicylic Acid which helps shrink the appearance of spots, Centella Asiatica (Cica) helps reduce redness and Canadian Willowherb helps soothe the skin.

The Pharmacy Show is the UK’s only national dedicated event for community and primary care pharmacy professionals. By exhibiting this year, Acncide+Purifide aims to showcase its key products to over 8,000 professionals in the community and primary care pharmacy sector.

Acnecide+Purifide will be exhibiting at stand H67 from 13th – 14th October 2024.

 

For full information about the Acnecide+Purifide ranges, visit: www.acnecide.co.uk

 


 

About Acnecide
Acne, spots… its personal. And it’s our sole focus day in day out. We cut through the maze of myths and get straight to work on the basic causes of acne and spots: bacteria and blocked pores. Acnecide offers effective skincare solutions across the journey of acne and blemish-prone skin. Developed by dermatologists, our medicinal products include 5% Benzoyl Peroxide, an active ingredient which is effective in combating the bacteria that causes acne. Our Acnecide Face Gel Spot Treatment and Face Wash Spot Treatments kill up to 95% of the spot-causing bacteria in 1 week and help unblock pores to control future breakouts. These treatments are available to self-select in the main skincare aisles as well as over the counter in most pharmacies. We also have a dermacosmetic range to help to cleanse, moisturise and protect sensitive spot-prone skin - offering some everyday TLC.

About Purifide
From the makers of the UK’s no.1 selling acne treatment brand, Acnecide, Purifide is a range of smart skincare for spot and blemish-prone skin. Within the range of 6 targeted skincare cleansers and moisturisers, as well as brand new spot patches, there are formulations to help rebalance skin during breakouts or alongside topical spot treatments and others to help maintain clear skin by controlling the key causes of spots and blemishes: excess oil, blocked pores, and spot-causing bacteria.

About Galderma

Galderma is the world’s largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by a complete dedication to dermatology. We deliver an innovative, science-back portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine. Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes. Because we understand that the skin, we’re in shapes our life stories, we are advancing dermatologist for every skin story. For more information: www.galderma.com.

Media contact:

Black&White Communications

Email: acnecide@blackandwhitecomms.com

Acnecide Face 5% w/w Gel & Acnecide Face Wash 5% w/w Gel. Active Ingredient: 5 % w/w benzoyl peroxide. Presentation:  White to off-white smooth gel. Indications: For the topical treatment of mild acne affecting the face only. For adults and adolescents aged 12 years or over. Dosage and Administration: Gel: Before each application, the skin should be cleaned and dried. When first used, apply in a thin layer once daily or as directed to the affected areas before going to bed. After 2-3 days, if well-tolerated, the frequency of application can be increased to twice daily, in the morning and the evening. Persons with sensitive skin should apply the gel once daily before going to bed.

Wash Gel: When first used, apply once daily to cover the affected skin areas. After 2-3 days, if well-tolerated, the frequency of application can be increased to twice daily, in the morning and the evening. Contraindications: Known sensitivity to benzoyl peroxide or any of the excipients. Precautions and Warnings: A mild burning sensation will probably be felt on first application and some reddening and peeling of the skin will occur within a few days. During the first weeks of treatment a sudden increase in peeling will occur in most people. If severe irritation occurs, patients should be directed to temporarily discontinue use. If treatment is then restarted, patients should be directed to apply the product less frequently and discontinue use altogether if irritation occurs again. Acnecide may cause swelling and blistering of the skin. If any of these symptoms occur, medication has to be discontinued. Treatment should be discontinued, and medical advice sought if scarring occurs or if there is no change or a deterioration in the patient’s condition. Patients should be advised that excessive application will not improve efficacy but may increase the risk of skin irritation. Acnecide should not come into contact with the eyes, mouth, angles of the nose or mucous membranes.  If the preparation enters the eye, wash thoroughly with water.  Caution should be exercised when applying the drug to the neck and other sensitive areas. Sunlamps should not be used and deliberate or prolonged exposure to sunlight or UV radiation should be avoided or minimised; patients should use protective sunscreen and wear protective clothing when this cannot be done.  Contact with any coloured material including hair and dyed fabrics may result in bleaching or discoloration. Due to the risk of sensitisation, Acnecide should not be applied on damaged skin.  Acnecide Face 5% w/w Gel contains 40 mg of propylene glycol (E1520) in each gram, which is equivalent to 4.0 %w/w. It may cause skin irritation. Interactions: Drugs with desquamative, irritant and drying effects should not be used concurrently. Pregnancy and Lactation: Acnecide should only be used by pregnant or breastfeeding women under medical supervision. Side Effects: Very common (≥1/10) adverse events include dry skin, erythema, skin exfoliation (peeling) and skin burning sensation. Common (≥1/100 to <1/10) adverse events include pruritis, pain of skin (pain, stinging), skin irritation (irritant contact dermatitis). Uncommon (≥1/1,000 to <1/100) adverse events include allergic contact dermatitis. Swelling face and allergic reactions, including application site hypersensitivity and anaphylaxis (frequency not known) have been reported during post-marketing surveillance. Prescribers should consult the summary of product characteristics in relation to other side effects. Marketing Authorisation Holder: Galderma (U.K.) Limited, Evergreen House North, Grafton Place, London, England, NW1 2DX. MA Number: Gel: PL 10590/0069. Wash Gel: PL 10590/0070. Legal Category: GSL. GB-ACC-2400071 September 2024.

Adverse events should be reported.  Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.  Adverse events should also be reported to Galderma (U.K.) Limited.

E-mail:medinfo.uk@galderma.com Tel:  +44 (0)300 3035674

View all Exhibitor News
Loading

2024 PARTNERS AND SPONSORS

Supported By

Sponsored By

Platinum App Sponsor

Gold App Sponsor

Education Partners

Official Media Partner

Official Digital Partner

Official Publications

Media Partners

Digital Partner

Charity Partners

Official Covid & Flu Jab Training

Career Partner